1826859-79-3
1826859-79-3
Chemical Structure
Atesidorsen sodium
Synonym(s): COR-004 sodium; ATL1103 sodium; ISIS 227452 sodium
- CAS No.: 1826859-79-3
- Formula:N/A
- Molecular Weight:7164 (free acid)
SMILES: [Atesidorsen (sodium)]
Biological Activity: Atesidorsen (COR-004, ATL1103) sodium is an antisense oligonucleotide targeting the growth hormone receptor (GHR). Atesidorsen sodium binds to GHR mRNA, inhibits human GHR translation, and reduces GHR synthesis through RNase H degradation. Atesidorsen sodium reduces hepatic GHR mRNA and serum IGF-I. Atesidorsen sodium can be used in research related to acromegaly[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Atesidorsen sodium | 98.58% | Atesidorsen (COR-004, ATL1103) sodium is an antisense oligonucleotide targeting the growth hormone receptor (GHR). Atesidorsen sodium binds to GHR mRNA, inhibits human GHR translation, and reduces GHR synthesis through RNase H degradation. Atesidorsen sodium reduces hepatic GHR mRNA and serum IGF-I. Atesidorsen sodium can be used in research related to acromegaly. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Golounina O, et al. Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference. Frontiers in endocrinology. 2025;16:1525373.
- [2]. Trainer PJ, et al. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology. 2018 Aug;179(2):97-108. [Content Brief]
- [3]. Kasuki L, et al. Innovative therapeutics in acromegaly. Best Practice & Research Clinical Endocrinology & Metabolism. 2022 Dec 1;36(6):101679.
